Clinical Trial Update: A Study of the EP4 Antagonist CR6086 in Combination With Methotrexate, in DMARD-naïve Patients With Early Rheumatoid Arthritis [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the EP4 antagonist CR6086 combined with methotrexate in DMARD-naïve patients with early rheumatoid arthritis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• CR6086 (EP4 antagonist)
• METHOTREXATE (METHOTREXATE)

Snippet

Sponsor: Rottapharm Biotech | Conditions: Rheumatoid Arthritis, DMARD-naive and Early Disease Patients | Phase 2 | Status: COMPLETED